Prevnar 20 (pneumococcal 20-valent conjugate vaccine) / Pfizer - LARVOL DELTA

Evaluating the impact of population-based and cohort-based models in cost-effectiveness analysis: a case study of pneumococcal conjugate vaccines in infants in Germany. (PubMed, J Med Econ) - "This analysis highlights the importance of accurately identifying the relevant population when conducting CEAs of vaccines. This is particularly crucial when a vaccine produces indirect effects in individuals who are not directly vaccinated, as this otherwise leads to an underestimation of cost-effectiveness."

HEOR • Journal • Infectious Disease • Pediatrics • Pneumococcal Infections

A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant (clinicaltrials.gov) - P1 | N=100 | Recruiting | Sponsor: Pfizer | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pneumococcal Infections

A Study to Learn About How a New Pneumococcal Vaccine Works in Children (clinicaltrials.gov) - P2 | N=225 | Active, not recruiting | Sponsor: Pfizer | Recruiting ➔ Active, not recruiting | Trial completion date: Sep 2025 ➔ Feb 2026 | Trial primary completion date: Sep 2025 ➔ Feb 2026

Enrollment closed • Trial completion date • Trial primary completion date • Infectious Disease • Pneumococcal Infections

A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan (clinicaltrials.gov) - P3 | N=401 | Active, not recruiting | Sponsor: Pfizer | Trial completion date: Feb 2026 ➔ Sep 2025 | Trial primary completion date: Feb 2026 ➔ Sep 2025

Trial completion date • Trial primary completion date • Infectious Disease • Pneumococcal Infections

The Role of Adult Pneumococcal Vaccination in Combating Antimicrobial Resistance: An Indian Perspective. (PubMed, J Assoc Physicians India) - "Addressing these barriers through increased public awareness, dedicated vaccination centers, and collaboration with government and insurance stakeholders is essential to improve coverage and reduce the disease burden. Integrating vaccination into antimicrobial stewardship programs (AMSP), rational antibiotic use, and improved diagnostics are key to mitigating AMR."

Journal • Review • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Cost-effectiveness analysis of 20-valent anti-pneumococcal vaccination in the Spanish pediatric population. (PubMed, Expert Rev Pharmacoecon Outcomes Res) - "PCV20demonstrated dominance over both alternatives, with 100% of 1,000 probabilisticsensitivity analysis iterations indicating PCV20 dominance. Incorporating PCV20 3 + 1 into the Spanish pediatricNIP was predicted to be more effective at a lower cost than PCV13 2 + 1 and PCV152 + 1 due to its broader serotype coverage and enhanced protection againstpneumococcal disease."

HEOR • Journal • Infectious Disease • Otorhinolaryngology • Pediatrics • Pneumococcal Infections • Pneumonia

RATES OF INFLUENZA AND PNEUMOCOCCAL VACCINATION AND CORRELATION WITH SURVIVAL IN MULTIPLE MYELOMA PATIENTS: A REAL-LIFE SURVEY (EHA 2025) - "FV was performed in more than 70% of patients while less than a half of patients received PV, in one third of cases with a sub-optimal sequential administration of a polysaccharide vaccine (Pneumovax) followed by a pneumococcal conjugate vaccine (Prevnar13 or Prevnar20). In MM a response to PV is detectable, independently of preexisting hypogammaglobulinemia and possibly of treatment-induced immunodepression, even if a drop in the serum response overtime suggests the need of a dedicated schedule with a multidisciplinary approach, especially in the setting of RRMM patients."

Clinical • Pneumococcal vaccines • CNS Disorders • Depression • Hematological Malignancies • Infectious Disease • Influenza • Multiple Myeloma • Oncology • Pneumococcal Infections • Psychiatry • Respiratory Diseases

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=580 | Recruiting | Sponsor: Sanofi | Trial completion date: May 2027 ➔ Aug 2027 | Trial primary completion date: May 2027 ➔ Aug 2027

Trial completion date • Trial primary completion date • Infectious Disease • Pneumococcal Infections

A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant (clinicaltrials.gov) - P1 | N=100 | Not yet recruiting | Sponsor: Pfizer

New P1 trial • Infectious Disease • Pneumococcal Infections

A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults (clinicaltrials.gov) - P1 | N=400 | Not yet recruiting | Sponsor: Pfizer

New P1 trial • Infectious Disease • Pneumococcal Infections

Cost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine (PCV20) to prevent pneumococcal disease in the Greek pediatric population. (PubMed, Expert Rev Vaccines) - "Scenario analyses showed that PCV20 remained dominant under a 2 + 1 dosing schedule. Vaccination with PCV20, whether in a 2 + 1 or a 3 + 1 schedule, was estimated to be a dominant vaccination strategy over PCV15 or PCV13 for the prevention of pneumococcal disease in Greek infants, as expansion of serotype coverage prevents additional morbidity and costs."

HEOR • Journal • Infectious Disease • Otorhinolaryngology • Pediatrics • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Health and economic impact of 20-valent pneumococcal conjugate vaccine for adults aged 66-84 years in Japan and shiga prefecture. (PubMed, Expert Rev Pharmacoecon Outcomes Res) - "In local-level analysis, the introduction of PCV20 required initial costs but resulted in greater cost savings related to medical expenses (-JPY424 and -JPY430 per person) and nursing care (-JPY560 and -JPY575 per person) compared to PPSV23 and no vaccination, respectively. PCV20 is cost-effective compared with PPSV23 and no vaccination in adults aged 66-84 years, which could reduce the future healthcare burden in Japan."

HEOR • Journal • Infectious Disease • Pneumococcal Infections

VIVID: Vaccine Immunity and Inflammation in the Aging Person Living With HIV (clinicaltrials.gov) - P4 | N=250 | Recruiting | Sponsor: Hennepin Healthcare Research Institute | Trial completion date: Dec 2030 ➔ Jun 2029 | Trial primary completion date: Dec 2029 ➔ Sep 2028

Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • Inflammation

Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years in Singapore. (PubMed, Value Health Reg Issues) - "Cost-effectiveness analysis suggests use of PCV20-in lieu of current Singapore Ministry of Health recommendations for adult pneumococcal vaccination-would represent a cost-effective use of scarce healthcare resources."

HEOR • Journal • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

0100 - INDUSTRY SYMPOSIUM 04 (NOT INCLUDED IN THE MAIN EVENT CME/CPD CREDIT): From Data to Vaccination: Understanding the Science and Need for PCV20 (ESPID 2025) - "A panel of leading experts will examine the evolving epidemiology of pediatric pneumococcal disease, the critical need for broader serotype coverage, and the anticipated impact of next-generation pneumococcal conjugate vaccines (PCVs). With a particular focus on PCV20, discussions will highlight the pressing need for its timely implementation in national immunization programs to address gaps in protection and prevent unnecessary disease burden."

CME • Infectious Disease • Pneumococcal Infections

Advancing Health Economics: Incorporating AMR Impact Into Pneumococcal Vaccine Assessment (ISPOR 2025) - "This pragmatic modelling approach effectively demonstrates the significant potential of PCV infant immunization in reducing antibiotic prescriptions and resistance. Additionally, the framework has identified key data gaps necessary for improving future modelling efforts. These findings advocate for the inclusion of AMR into cost-effectiveness models and to incorporate AMR impact into the health technology assessment and appraisals of vaccines."

HEOR • Pneumococcal vaccines • Infectious Disease • Pneumococcal Infections

Meta-analysis of Economic Evaluations of Higher-Valent Pneumococcal Conjugate Vaccines For Seniors in High-Income Countries (ISPOR 2025) - "This study suggests that higher-valent PCVs are generally cost-effective for the senior population in high-income countries, including PCV20 relative to PCV15. These findings can provide valuable insights for vaccination policy decisions in regions contemplating the use of higher-valent PCVs for older adults, supporting the efficient allocation of healthcare resources."

HEOR • Retrospective data • Infectious Disease • Pneumococcal Infections

Impact of delaying PCV20 implementation in France's pediatric national immunization program: A population-based Markov model. (PubMed, Infect Dis Now) - "Rapid implementation of PCV20 is estimated to prevent thousands of cases and deaths over two years compared to the continuous PCV15 or PCV13 use, reducing significant negative impact to public health outcomes and waste of health care resources."

Journal • Infectious Disease • Pediatrics • Pneumococcal Infections

The Value of Pneumovax Testing in the Prevnar 20 Era (CIS 2025) - "Even in subjects who have previously received PCV13 or PCV20, there is still diagnostic utility in administration of PPSV23 and evaluation of the response to the unique serotypes as a means of assessing anti-polysaccharide antibody responses."

Immunology • Infectious Disease • Pneumococcal Infections • Primary Immunodeficiency

Cost-effectiveness analysis of implementing 20-valent pneumococcal conjugate vaccine into the Romanian pediatric national immunization program. (PubMed, J Med Econ) - "The majority of sensitivity and scenario analyses of both pairwise comparisons were aligned with the base case. The results of this analysis indicate that PCV20 implementation into the Romanian pediatric NIP would greatly reduce pneumococcal disease burden and would be a cost-effective approach versus PCV13 or PCV15 from a societal perspective over 10 years."

HEOR • Journal • Infectious Disease • Pediatrics • Pneumococcal Infections

A Study to Learn About How Well the Prevnar 20 Vaccine Works for Pneumonia in People Who Are 65 Years and Older (clinicaltrials.gov) - P=N/A | N=22234435 | Active, not recruiting | Sponsor: Pfizer | Trial completion date: Apr 2025 ➔ Sep 2025 | Trial primary completion date: Apr 2025 ➔ Sep 2025

Real-world evidence • Trial completion date • Trial primary completion date • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

An Italian cost-utility analysis of 20-Valent pneumococcal conjugate vaccine for routine vaccination in infants. (PubMed, J Med Econ) - "The introduction of PCV20 as a vaccination strategy for children in Italy represents a cost-effective and clinically advantageous option. Its implementation can reduce the burden of pneumococcal disease and associated healthcare costs, improving public health outcomes and the economic efficiency of the healthcare system."

HEOR • Journal • Infectious Disease • Pediatrics • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Phase 2 Trial to Evaluate Safety and Immunogenicity of Inventprise's (IVT) 25-valent Pneumococcal Conjugate Vaccine (IVT PCV-25) in Healthy Infants (clinicaltrials.gov) - P2 | N=421 | Active, not recruiting | Sponsor: Inventprise Inc. | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2025 ➔ Dec 2026

Enrollment closed • Trial completion date • Infectious Disease • Pneumococcal Infections

Indirect Comparison of PCV20 Immunogenicity with PCV10 in Pediatric 3 + 1 and 2 + 1 Schedules. (PubMed, Infect Dis Ther) - "The comparable immunogenicity of PCV20 versus PCV10 in 2 + 1 and 3 + 1 schedules suggests that PCV20 will have similar effectiveness for the ten serotypes included in both vaccines, including for direct protection during infancy and toddler age, while also expanding serotype coverage. Effectiveness for PCV20 needs to be confirmed in post-marketing studies."

Journal • Infectious Disease • Pediatrics • Pneumococcal Infections • Pneumonia

A Study to Learn About How a New Pneumococcal Vaccine Works in Infants (clinicaltrials.gov) - P2 | N=800 | Recruiting | Sponsor: Pfizer | N=500 ➔ 800 | Trial completion date: Aug 2026 ➔ May 2027 | Trial primary completion date: Aug 2026 ➔ May 2027

Enrollment change • Trial completion date • Trial primary completion date • Infectious Disease • Pneumococcal Infections